Allink Biotherapeutics, Inc., a clinical-stage biotech company developing advanced antibody-drug conjugates and multi-specific antibody therapies for oncology and immunology, announced that it has successfully closed extension rounds of its Series A financing, raising 47 million US dollars. The rounds were led by existing investor Legend Capital and new participant Meituan Long-Z Investment, alongside other returning and new investors including Lanchi Ventures, Yuanbio Venture Capital, 5Y Capital, Lapam Capital, and Runzhang Venture Capital.
Health Technology Insights: Astrin Biosciences Forms SAB to Boost AI Cancer Detection
The funds will accelerate global clinical development for AllinkBio’s two leading programs, each with distinct competitive advantages. ALK201, a potential first- and best-in-class FGFR2b-targeted ADC, has shown promising efficacy across multiple tumor types while maintaining a favorable safety profile. This positions ALK201 as a potential backbone therapy for tumors overexpressing FGFR2b. In parallel, early clinical results for ALK202 support the potential of its EGFR/cMET bispecific ADC as a cornerstone treatment for non-small cell lung cancer. Both programs are being expanded to include clinical evaluation across a wider range of biomarker-defined tumor types and patient populations.
Health Technology Insights: Mirum Pharma to Acquire Bluejay Therapeutics for Rare Disease
AllinkBio is developing these assets through a biomarker-driven strategy aimed at demonstrating efficacy in a broad spectrum of solid tumors. In the near term, the company plans to initiate combination therapy studies to explore therapeutic potential in larger front-line patient populations. These efforts are designed to move ALK201 and ALK202 toward pivotal trial readiness while establishing differentiated profiles in their respective target indications.
Beyond ADC technology, AllinkBio is also building a proprietary masked T-cell engager platform to expand the application of TCEs in solid tumors. In the immunology sector, the company is advancing a portfolio of first-in-class bi- and multi-specific antibody drug candidates. These programs are based on rational biological design and aim to provide next-generation solutions for patient populations underserved by current therapies.
Hui Feng, Ph.D., Founder and Chief Executive Officer of AllinkBio, said the support from investors has been instrumental in driving the company’s clinical roadmap forward. She emphasized that beyond the two lead programs, the company’s discovery engine is fully activated and poised to deliver innovative drug candidates that will create further value in the near future.
Tan Hong, Managing Director at Legend Capital, highlighted that their continued investment reflects confidence in AllinkBio’s execution capabilities and development strategy. He noted that the rapid clinical progress of the company’s two lead assets validates the ADC platform and represents significant potential for value creation.
Xuejing Guo, Managing Director and Head of Healthcare at Meituan Long-Z Investment, praised AllinkBio’s combination of international vision and operational excellence. Guo expressed excitement about the potential of the company’s technology platform and its ability to translate innovative discoveries into therapies with global impact, ultimately benefiting patients worldwide.
Health Technology Insights: Reid Waldman Wins Entrepreneur of the Year in Life Sciences
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
